Two-, three-course neoadjuvant chemo equally feasible in locally advanced ESCC
The two- and three-course DCF (docetaxel, cisplatin, and fluorouracil) regimens are both useful in the neoadjuvant treatment of locally advanced oesophageal squamous cell cancer (ESCC), with additional courses yielding better response without the increased risk of adverse events or postoperative morbidity, according to the results of a phase II trial.
